Literature DB >> 29380260

Long-term follow-up in the endovascular treatment of intracranial aneurysms with flow-diverter stents: update of a single-centre experience.

Giuseppe Guzzardi1, Carmelo Stanca2, Paolo Cerini2, Bruno Del Sette2, Ignazio Divenuto3, Emanuele Malatesta4, Alessandro Carriero2, Alessandro Stecco2.   

Abstract

INTRODUCTION: Flow-diverter stents are becoming a useful tool in treating patients with intracranial aneurysms with suitable anatomical feature. Purpose of this study was to evaluate effectiveness and safety of endovascular treatment with flow-diverting stents (FD) in unruptured intracranial aneurysms.
METHODS: From May 2009 and May 2014, we treated 49 patients with a total of 58 aneurysms, with FD technique. All patients were treated electively, under general anesthesia and were administered single antiplatelet drug 5 days before the procedure and double antiplatelet therapy for 3 months afterwards. Fifteen of the patients were asymptomatic, eight had headache, thirteen patients presented symptoms due to mass effect of the aneurysm on CNS structures, twelve were treated due to a post-surgical relapse and one patient presented relapsing TIAs due to distal embolization from the aneurysm dome. Choice of FD treatment was done according to aneurysm anatomy (fusiform over saccular, dome/neck ratio < 2) and whenever conventional treatment (coil embolization) appeared difficult (eg. Large aneurysm neck, fusiform aneurysms or difficult sac catheterization). We considered a dome/neck ratio > 2 as the only exclusion criteria.
RESULTS: Successful stent deployment was achieved in 50 procedures out of 52 (94.34%) while overall mortality was 2% (1/49). Forty-eight patients were evaluated at long-term follow-up for a total of 56 treated aneurysms. At 3 months, follow-up 75% (42/56) of the aneurysms were excluded from intracranial circulation, at 6 months 80.35% (45/56) and at 12 months 84% (47/56). Stent patency was observed in 100% of patients at short and long-term follow-up, with only two cases of intimal hyperplasia at 3 months, without any further complications.
CONCLUSIONS: According to our study FD repair of unruptured intracranial aneurysms appeared to be a safe and effective technique, especially in selected patients with hostile anatomy for traditional embolization.

Entities:  

Keywords:  Endovascular treatment; Flow-diverter stent; Intracranial aneurysm

Mesh:

Year:  2018        PMID: 29380260     DOI: 10.1007/s11547-018-0857-8

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  25 in total

1.  Towards European standards in neuroradiology.

Authors:  P Lasjaunias
Journal:  Acta Neurochir Suppl       Date:  2001

2.  Flow-diverter silk stent for the treatment of intracranial aneurysms: 1-year follow-up in a multicenter study.

Authors:  J Berge; A Biondi; P Machi; H Brunel; L Pierot; J Gabrillargues; K Kadziolka; X Barreau; V Dousset; A Bonafé
Journal:  AJNR Am J Neuroradiol       Date:  2012-02-02       Impact factor: 3.825

3.  Unruptured intracranial aneurysms--risk of rupture and risks of surgical intervention.

Authors: 
Journal:  N Engl J Med       Date:  1998-12-10       Impact factor: 91.245

4.  Parent artery occlusion: a well-established technique.

Authors:  C M Benson; D M Pelz; S P Lownie
Journal:  AJNR Am J Neuroradiol       Date:  2015-04-16       Impact factor: 3.825

5.  The "Remodelling Technique" in the Treatment of Wide Neck Intracranial Aneurysms. Angiographic Results and Clinical Follow-up in 56 Cases.

Authors:  J Moret; C Cognard; A Weill; L Castaings; A Rey
Journal:  Interv Neuroradiol       Date:  2001-05-15       Impact factor: 1.610

6.  Endovascular treatment of intracranial aneurysms with flow-diverter stents: preliminary single-centre experience.

Authors:  Emanuele Malatesta; Nunzio Paolo Nuzzi; Ignazio Divenuto; Rita Fossaceca; Mariangela Lombardi; Paolo Cerini; Giuseppe Guzzardi; Alessandro Stecco; Cosma Andreula; Alessandro Carriero
Journal:  Radiol Med       Date:  2013-06-26       Impact factor: 3.469

7.  Controlled pressure-volume factors in the enlargement of intracranial aneurysms.

Authors:  G M Austin; W Schievink; R Williams
Journal:  Neurosurgery       Date:  1989-05       Impact factor: 4.654

8.  High-profile flow diverter (silk) implantation in the basilar artery: efficacy in the treatment of aneurysms and the role of the perforators.

Authors:  Zsolt Kulcsár; Ulrike Ernemann; Stephan G Wetzel; Alexander Bock; Sophia Goericke; Vasilis Panagiotopoulos; Michael Forsting; Daniel A Ruefenacht; Isabel Wanke
Journal:  Stroke       Date:  2010-07-08       Impact factor: 7.914

9.  Treatment of intracranial aneurysms by functional reconstruction of the parent artery: the Budapest experience with the pipeline embolization device.

Authors:  I Szikora; Z Berentei; Z Kulcsar; M Marosfoi; Z S Vajda; W Lee; A Berez; P K Nelson
Journal:  AJNR Am J Neuroradiol       Date:  2010-02-11       Impact factor: 3.825

10.  Curative endovascular reconstruction of cerebral aneurysms with the pipeline embolization device: the Buenos Aires experience.

Authors:  Pedro Lylyk; Carlos Miranda; Rosana Ceratto; Angel Ferrario; Esteban Scrivano; Hugh Ramirez Luna; Aaron L Berez; Quang Tran; Peter K Nelson; David Fiorella
Journal:  Neurosurgery       Date:  2009-04       Impact factor: 4.654

View more
  2 in total

1.  Intravenous versus intra-arterial digital subtraction angiography: Occlusion rate and complication assessment of experimental aneurysms after flow diverter treatment in rabbits.

Authors:  Andreas Simgen; Toshiki Tomori; Hagen Bomberg; Umut Yilmaz; Christian Roth; Wolfgang Reith; Ruben Mühl-Bennighaus
Journal:  Interv Neuroradiol       Date:  2018-11-04       Impact factor: 1.610

2.  Flow diverter stents with hydrophilic polymer coating for the treatment of acutely ruptured aneurysms using single antiplatelet therapy: Preliminary experience.

Authors:  Giuseppe Guzzardi; Andrea Galbiati; Carmelo Stanca; Bruno Del Sette; Andrea Paladini; Christian Cossandi; Alessandro Carriero
Journal:  Interv Neuroradiol       Date:  2020-08-16       Impact factor: 1.610

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.